Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...
Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...
Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...
Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...
Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has obtained regulatory approval from...
Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...
Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...
Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...
CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...
Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...
Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...
Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled
China’s Ministry of Industry and Information Technology, Ministry of Commerce, National Health Commission (NHC), and...
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...
Amgen Announces $900M Investment to Expand Ohio Manufacturing
US biotech leader Amgen (NASDAQ: AMGN) announced a USD 900 million investment to expand its...